1. Executive Summary (Confidence: High)

CeQur Corporation, headquartered in Horw, Switzerland, is a major player in the metabolic health sector, dedicated to simplifying insulin delivery for people with Type 1 and Type 2 diabetes. The company’s primary product is the CeQur Simplicity™, a wearable, injection-free insulin patch that holds up to 200 units of rapid-acting insulin and can be worn for up to four days. CeQur has demonstrated strong commercial traction, raising a total of $392 million, including a massive $120 million Series D round in January 2025 to scale its sales and manufacturing operations. With FDA 510(k) clearance for extended wear and a growing sales force across the United States, CeQur is positioned as a leading alternative to both standard insulin pens and complex electronic pumps.